197 related articles for article (PubMed ID: 18021496)
21. Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study.
De Deyn PP; Eriksson H; Svensson H;
Int J Geriatr Psychiatry; 2012 Mar; 27(3):296-304. PubMed ID: 21538537
[TBL] [Abstract][Full Text] [Related]
22. [Generic quetiapine in the treatment of acute schizophrenia and schizoaffective disorder].
György B; Robert K; László C; Andrea J;
Neuropsychopharmacol Hung; 2008 Dec; 10(5):293-303. PubMed ID: 19419015
[TBL] [Abstract][Full Text] [Related]
23. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
Zhong KX; Sweitzer DE; Hamer RM; Lieberman JA
J Clin Psychiatry; 2006 Jul; 67(7):1093-103. PubMed ID: 16889453
[TBL] [Abstract][Full Text] [Related]
24. [Administration of once-daily extended release quetiapine in schizophrenic disorders].
Bartkó G
Neuropsychopharmacol Hung; 2007 Dec; 9(4):189-95. PubMed ID: 18510263
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
Liebowitz M; Lam RW; Lepola U; Datto C; Sweitzer D; Eriksson H
Depress Anxiety; 2010 Oct; 27(10):964-76. PubMed ID: 20734365
[TBL] [Abstract][Full Text] [Related]
26. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies.
Meulien D; Huizar K; Brecher M
Hum Psychopharmacol; 2010 Mar; 25(2):103-15. PubMed ID: 20196185
[TBL] [Abstract][Full Text] [Related]
27. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.
Figueroa C; Brecher M; Hamer-Maansson JE; Winter H
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):199-204. PubMed ID: 18948162
[TBL] [Abstract][Full Text] [Related]
29. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
Bauer M; Dell'osso L; Kasper S; Pitchot W; Dencker Vansvik E; Köhler J; Jørgensen L; Montgomery SA
J Affect Disord; 2013 Oct; 151(1):209-19. PubMed ID: 23810357
[TBL] [Abstract][Full Text] [Related]
30. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study.
Khan A; Atkinson S; Mezhebovsky I; She F; Leathers T; Pathak S
Ann Clin Psychiatry; 2014 Feb; 26(1):3-18. PubMed ID: 24660224
[TBL] [Abstract][Full Text] [Related]
31. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia.
Li Q; Su YA; Liu Y; Chen JX; Tan YL; Yang FD; Si TM
Clin Pharmacokinet; 2014 May; 53(5):455-65. PubMed ID: 24385309
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics.
De Nayer A; Windhager E; Irmansyah ; Larmo I; Lindenbauer B; Rittmannsberger H; Platz T; Jones A; Whiteford J; Altman C
Int J Psychiatry Clin Pract; 2003; 7(1):59-66. PubMed ID: 24937244
[TBL] [Abstract][Full Text] [Related]
34. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.
Bandelow B; Chouinard G; Bobes J; Ahokas A; Eggens I; Liu S; Eriksson H
Int J Neuropsychopharmacol; 2010 Apr; 13(3):305-20. PubMed ID: 19691907
[TBL] [Abstract][Full Text] [Related]
35. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.
Katzman MA; Brawman-Mintzer O; Reyes EB; Olausson B; Liu S; Eriksson H
Int Clin Psychopharmacol; 2011 Jan; 26(1):11-24. PubMed ID: 20881846
[TBL] [Abstract][Full Text] [Related]
36. Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study.
Li Y; Li H; Liu Y; Yan X; Yue Y; Qian M
Curr Med Res Opin; 2012 Oct; 28(10):1725-32. PubMed ID: 22978771
[TBL] [Abstract][Full Text] [Related]
37. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study.
Riesenberg RA; Baldytcheva I; Datto C
Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166
[TBL] [Abstract][Full Text] [Related]
38. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
39. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
40. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms.
Riedel M; Müller N; Strassnig M; Spellmann I; Engel RR; Musil R; Dehning S; Douhet A; Schwarz MJ; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2005 Dec; 255(6):432-7. PubMed ID: 16267634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
